Thromboxane A2 (TXA2) and prostacyclin (PGI2) are derived from prostaglandin H2 (PGH2) via opposing enzymes — thromboxane synthase (in platelets) and prostacyclin synthase (in vascular endothelium), respectively. Low-dose aspirin selectively inhibits platelet COX-1 irreversibly. Platelets lack nuclei and cannot re-synthesize COX-1. Endothelial cells recover COX activity within hours by new protein synthesis. This forms the pharmacological basis for cardioprotection. Why is it important that aspirin's effect on platelet TXA2 is NOT offset by equal suppression of endothelial PGI2 at low doses?

• A Endothelial cells have higher concentrations of arachidonic acid than platelets, overcoming partial COX inhibition
• B Because platelets cannot regenerate COX-1 (anucleate), platelet TXA2 synthesis is permanently suppressed for the platelet's 7-10 day lifespan, while endothelial PGI2 production recovers through new COX synthesis ✓
• C Endothelial prostacyclin synthase is less sensitive to aspirin than platelet thromboxane synthase
• D Low-dose aspirin preferentially acetylates platelet COX-1 serine 530 but not endothelial COX-2

Explanation

The differential effect of low-dose aspirin on platelet TXA2 versus endothelial PGI2 is entirely based on the anucleate nature of platelets versus the nucleated endothelial cells. Aspirin irreversibly acetylates COX-1 at Ser-530, permanently inactivating it in platelets for their entire lifespan (7-10 days) since platelets cannot synthesize new COX protein. Endothelial cells (which have nuclei) can re-synthesize COX-1 (and COX-2) within hours. Thus, with once-daily low-dose aspirin dosing, platelet TXA2 (pro-thrombotic, pro-aggregatory, vasoconstrictive) remains persistently suppressed while endothelial PGI2 (anti-thrombotic, vasodilatory) largely recovers between doses. This net shift in the TXA2/PGI2 balance toward the anti-aggregatory PGI2 effect underlies aspirin's cardioprotective antiplatelet mechanism.

Reference: Harper's Illustrated Biochemistry, 32nd ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.